What is ITM?
ITM operates at the intersection of biotechnology and nuclear medicine, specializing in the development of next-generation radiopharmaceutical therapeutics and diagnostics. The company is uniquely positioned within the precision oncology landscape, utilizing a proprietary pipeline that integrates high-quality radioisotopes with targeted molecules. With over two decades of pioneering expertise, ITM maintains a central industry position, supported by an established global network that facilitates the production and distribution of life-saving medical isotopes. Their commitment to improving patient outcomes through targeted treatment protocols has made them a vital partner for clinicians and healthcare providers worldwide.
How much funding has ITM raised?
ITM has raised a total of $664.9M across 6 funding rounds:
Private Equity
$22M
Debt
$109M
Private Equity
$30M
Private Equity
$36.4M
Other Financing Round
$205M
Debt
$262.5M
Private Equity (2016): $22M, investors not publicly disclosed
Debt (2021): $109M led by Petrichor Healthcare Capital Management
Private Equity (2021): $30M supported by Portland Holdings and FRIBA Investment
Private Equity (2022): $36.4M featuring Indigenous Critical Infrastructure Fund Canada and Portland Investment Counsel
Other Financing Round (2024): $205M backed by Athos, BlackRock, Qatar Investment Authority, and Temasek
Debt (2025): $262.5M with participation from Blue Owl
Key Investors in ITM
Blue Owl
Blue Owl is an asset management company that specializes in capital solutions and direct lending.
BlackRock
BlackRock is a global investment management firm offering a comprehensive range of investment products, risk management, and advisory services to institutional and individual clients.
Qatar Investment Authority
Qatar Investment Authority is the sovereign wealth fund of the State of Qatar, managing and growing financial assets globally across diverse asset classes.
What's next for ITM?
With the recent influx of capital, ITM is well-positioned to accelerate its Phase 3 clinical studies and expand its global manufacturing footprint. The strategic focus remains on scaling the production of medical radioisotopes to meet the rising demand for targeted cancer therapies. As the company transitions into this next phase of development, the emphasis will be on optimizing its precision oncology pipeline and strengthening its competitive advantage in the radiopharma market. This major enterprise-level funding provides the necessary liquidity to sustain long-term innovation, ensuring that ITM remains at the forefront of therapeutic advancements in oncology.
See full ITM company page
